Chemicals & Small Molecules

NLG919 is an orally available potent inhibitor of the indoleamine-2,3- dioxygenase (IDO) pathway, a crucial pathway involved in allergic inflammation that mediates immunosuppressive effects through metabolization of tryptophan to kynurenine. NLG919 affects differentiation and proliferation of T cells by inducing downstream signaling via GCN2, mTOR and AHR, with values of Ki = 7 nM and EC50 = 75 nM. NLG919 is being investigated for the treatment of immunosuppression associated with cancer.

INCB024360 analog is an orally available hydroxyamidine and inhibitor of indoleamine 2,3- dioxygenase (IDO1), with an IC_50?? of 10 nM. It shows little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). INCB024360 analog displays potential immunomodulating and antineoplastic activities.

INCB024360 analog is an orally available hydroxyamidine and inhibitor of indoleamine 2,3- dioxygenase (IDO1), with an IC??₅₀ of 10 nM. It shows little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). INCB024360 analog displays potential immunomodulating and antineoplastic activities.

Epacadostat (INCB024360) is an orally available hydroxyamidine and inhibitor of indoleamine 2,3- dioxygenase (IDO1), with an IC₅₀?? of 10 nM. It shows little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). Epacadostat displays potential immunomodulating and antineoplastic activities.

Epacadostat (INCB024360) is an orally available hydroxyamidine and inhibitor of indoleamine 2,3- dioxygenase (IDO1), with an IC₅₀?? of 10 nM. It shows little activity against other related enzymes such as IDO2 or tryptophan 2,3-dioxygenase (TDO). Epacadostat displays potential immunomodulating and antineoplastic activities.

PI-103 is a multi-targeted inhibitor of PI3K for p110?, p110?, p110 ?, and p110? with reported IC50 values of 2 nM, 3 nM, 3 nM, and 15 nM respectively. PI-103 is less potent towards mTOR/DNA-PK with reported IC50 values of 30 nM and 23 nM respectively.

PI-103 is a multi-targeted inhibitor of PI3K for p110?, p110?, p110 ?, and p110? with reported IC50 values of 2 nM, 3 nM, 3 nM, and 15 nM respectively. PI-103 is less potent towards mTOR/DNA-PK with reported IC50 values of 30 nM and 23 nM respectively.

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.